Jean-Christophe Leroux
Jean-Christophe Leroux is a renowned pharmacist and professor specializing in pharmacology and drug delivery systems. He is currently serving as a professor at the ETH Zurich, where he heads the Institute of Pharmaceutical Sciences.
Early Life and Education[edit | edit source]
Jean-Christophe Leroux was born in France. He completed his PharmD from the University of Angers in 1989. He then pursued his PhD in Pharmaceutical Technology from the University of Geneva and University of Lausanne, which he completed in 1995.
Career[edit | edit source]
After completing his PhD, Leroux joined the University of Montreal as an assistant professor in the Faculty of Pharmacy. In 2002, he was promoted to the position of associate professor. During his tenure at the University of Montreal, he made significant contributions to the field of liposome research.
In 2006, Leroux moved to the ETH Zurich as a full professor. At ETH Zurich, he heads the Institute of Pharmaceutical Sciences. His research focuses on the development of novel drug delivery systems, with a particular emphasis on nanomedicine and nanotechnology.
Research and Contributions[edit | edit source]
Jean-Christophe Leroux's research has significantly advanced the field of pharmacology. His work on liposomes has led to the development of new drug delivery systems that can target specific cells or tissues in the body. This has potential applications in the treatment of various diseases, including cancer and inflammatory diseases.
Leroux's research also extends to the field of nanomedicine, where he has developed novel nanoparticles for drug delivery. These nanoparticles can be engineered to deliver drugs to specific parts of the body, improving the efficacy of treatment and reducing side effects.
Awards and Recognition[edit | edit source]
Jean-Christophe Leroux has received numerous awards and recognition for his contributions to the field of pharmacology. These include the Controlled Release Society's Young Investigator Award and the European Federation for Pharmaceutical Sciences' Innovative Pharmaceutical Technology Award.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
